Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) closed its fiscal second quarter ended Sept. 30, 2026 with $171.1 million in cash, a cushion the clinical-stage company will need as it advances a pipeline of novel serotonergic agonists through late-stage testing. The headline financial figure was a net loss of $103.1 million, compared with $33.7 million in the prior-year period, while operating expenses excluding share-based compensation rose to $39.6 million from $28.5 million. The company attributed the increase primarily to continued advancement of its Phase 3 clinical program, and cash used in operating activities totaled $35.3 million versus $34.5 million a year earlier.
For investors, the expense trajectory matters less than what those dollars are buying. During the quarter, Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) completed enrollment in APPROACH, its pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder. That milestone shifts the program from recruitment to execution, and it is the clearest near-term catalyst in a pipeline built on synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Enrollment continued in the EMBRACE and EXTEND studies, extending the company's late-stage footprint.
The strategic logic behind the spending is straightforward: major depressive disorder represents a large unmet need, and HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status that can accelerate review for therapies addressing serious conditions with preliminary clinical evidence suggesting substantial improvement over available options. If APPROACH delivers, the designation could compress the path to market and give Helus Pharma a differentiated position in a crowded mental health landscape.
Beyond HLP003, the company outlined plans to initiate a Phase 2 monotherapy study of HLP004 for generalized anxiety disorder in the first quarter of 2027 and expects to select a development candidate for its HLP005 program in the second half of 2027. That sequencing suggests management is building a multi-asset platform rather than staking the company on a single readout, though each additional program adds to the burn rate that produced the widened loss. The full press release is available at https://ibn.fm/yu74F.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom and Ireland. Additional company information is available at www.helus.com. The quarterly update was disseminated through BioMedWire, a communications platform focused on biotechnology, biomedical sciences and life sciences that operates within the Dynamic Brand Portfolio at IBN. That network distributes content through wire solutions via InvestorWire and provides editorial syndication to 5,000+ outlets, alongside social media distribution and a full array of tailored corporate communications solutions.
The implication is that Helus Pharma has moved from promising preclinical science into the costly, binary phase where clinical data determines value. With $171.1 million on hand and a Phase 3 program fully enrolled, the company has bought itself time, but the next several quarters will test whether its serotonin-pathway thesis translates into durable improvements for patients and a return for shareholders.


